MedTrace Logo

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

NCT07079735 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

Conditions

  • CMV Viremia
  • Heart Transplant Infection
  • Heart Transplant Failure and Rejection

Interventions

DRUG

Letermovir

CMV prophylaxis

DRUG

Valganciclovir

Standard therapy for CMV prophylaxis

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-12
Primary Completion
2028-01-17
Completion
2029-01-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07079735 on ClinicalTrials.gov